journal logo

Welcome to Oncogene

Publishing the latest research on the cellular and molecular biology of cancer including resistance to cancer therapies, and the development of better approaches to improving survival. 

Announcements

  • resistance

    NEW COLLECTION: Metastatic cancer is ultimately resistant to virtually all systemic therapies and continues to kill more than 10 million people per year around the world. This collection of articles from Oncogene and other related Springer Nature journals explores how treatment resistance arises in cancer. Further submissions welcome.

  • crispr

    NEW COLLECTION: Since its discovery as part of the adaptive immune system in bacteria, CRISPR-Cas9 has become an invaluable tool for genome editing with the potential to transform cancer therapies. This collection of articles from Oncogene and other related Springer Nature journals explores use of CRISPR-Cas9 technology to date and explores future possibilities. Further submissions welcome.

  • immune checkpoint

    NEW COLLECTION: The advent and validation of immune checkpoint inhibitors targeting the T cell receptors PD1 and CTLA have been 'game changers' in clinical cancer therapy. This collection of articles from Oncogene and other related Springer Nature journals explores the latest research in this area. Further submissions welcome.

  • twitter logo

    Join the Oncogene Twitter Community @oncogenejournal. Follow us to keep up-to-date with the latest research and news from Oncogene. Share your views, retweet and give us feedback.

Oncogene is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

Focus on…Breast Cancer Research

Breast cancer is the most common invasive cancer in women and the second leading cause of cancer death in women after lung cancer. Great strides have been made in treatment options and targeted therapies but research continues to further improve survival rate.
Focus

Advertisement